Annexon (ANNX) Return on Capital Employed (2020 - 2026)
Annexon's (ANNX) quarterly Return on Capital Employed came in at 87.52% in Q1 2026, down 2510.0% year-on-year from 3.63% in Q1 2025, and up 14.78% quarter-over-quarter from 102.7% in Q4 2025.
Annexon (ANNX) Return on Capital Employed (2020 - 2026) Analysis & Trends
Annexon's Return on Capital Employed history runs 7 years deep, the most recent figure standing at 87.52% for Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 2510.0% year-over-year to 87.52% in Q1 2026; TTM through Mar 2026 was 87.52%, a 2510.0% decrease from a year earlier, with the FY2025 full-year figure at 79.8%, down 2728.0% from the prior year.
- Return on Capital Employed advanced to 87.52% in Q1 2026 per ANNX's latest filing, from 102.7% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 35.34% in Q3 2024 and bottomed at 107.55% in Q3 2025.
- The 5-year median for Return on Capital Employed is 61.73% (2023), against an average of 64.94%.
- Across the five-year window, Return on Capital Employed jumped 3940 bps in 2024 and plunged 7221 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 52.65% in 2022, then retreated by 17 bps to 61.73% in 2023, then grew by 25 bps to 46.14% in 2024, then tumbled by 123 bps to 102.7% in 2025, then rose by 15 bps to 87.52% in 2026.
- Per Business Quant, the three latest ANNX Return on Capital Employed figures stand at 87.52% (Q1 2026), 102.7% (Q4 2025), and 107.55% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Annexon | 1.02 Bn | 798.41 Mn | - | -87.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -87.52% |
| Dec 31, 2025 | -102.70% |
| Sep 30, 2025 | -107.55% |
| Jun 30, 2025 | -82.68% |
| Mar 31, 2025 | -62.42% |
| Dec 31, 2024 | -46.14% |
| Sep 30, 2024 | -35.34% |
| Jun 30, 2024 | -37.56% |
| Mar 31, 2024 | -45.55% |
| Dec 31, 2023 | -61.73% |
| Sep 30, 2023 | -74.74% |
| Jun 30, 2023 | -65.10% |
| Mar 31, 2023 | -59.61% |
| Dec 31, 2022 | -52.65% |
| Sep 30, 2022 | -59.38% |
| Jun 30, 2022 | -67.77% |
| Mar 31, 2022 | -55.59% |
| Dec 31, 2021 | -47.21% |
| Sep 30, 2021 | -37.68% |
| Jun 30, 2021 | -29.91% |